Direct-to-Patient Apixaban Program Aims to Expand Access, Lower Out-of-Pocket Costs
Delayed Hypertension Diagnosis Tied to Higher Cardiovascular Risk, Lower Treatment Rates
FDA Approves Finerenone for Heart Failure With Mildly Reduced or Preserved LVEF
Improve Antiobesity Medication Adherence to Improve Results: Hamlet Gasoyan, PhD
40% of Patients With Heart Failure Don’t See Cardiologist Annually, Increasing Risk of Death
Improving Value in Cardiovascular Care Starts With More Accurate Testing: Merrill Stewart, MD
GME Funding Is Crucial to Addressing the Physician Shortage: Merrill Stewart, MD
Iptacopan Outshines Past C3G Treatments: Carla Nester, MD, MSA, FASN
Atrasentan Has Promising Long-Term Potential in IgA Nephropathy: Richard Lafayette, MD, FACP
Weight Regain After GLP-1 Discontinuation is Less Rapid in Real World: Hamlet Gasoyan, PhD
Cost and Infrastructure Slow Cardiac PET Adoption: Merrill Stewart, MD
Cost and Coverage Issues Drive GLP-1 Discontinuation: Hamlet Gasoyan, PhD
Not All Coronary Blockages Need Fixing: Merrill Stewart, MD
How Can PET Cardiac Stress Testing Prevent Invasive Procedures? Merrill Stewart, MD
Technological Advances in CV Care Depend on Human Resources: Antoine Keller, MD